Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia

Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tol...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Lima, Lisa M, Arellano, Martha, Holloway, Stacie, Shepard, Marian, McMillan, Stephanie, Khoury, Hanna Jean
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2010
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3262317/
https://ncbi.nlm.nih.gov/pubmed/22282699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S7158
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky